ZA928727B - 3-sulfonylamino-2(1H)-quinolone compounds, process for preparing them and pharmaceutical compositions containing them. - Google Patents

3-sulfonylamino-2(1H)-quinolone compounds, process for preparing them and pharmaceutical compositions containing them.

Info

Publication number
ZA928727B
ZA928727B ZA928727A ZA928727A ZA928727B ZA 928727 B ZA928727 B ZA 928727B ZA 928727 A ZA928727 A ZA 928727A ZA 928727 A ZA928727 A ZA 928727A ZA 928727 B ZA928727 B ZA 928727B
Authority
ZA
South Africa
Prior art keywords
branched
linear
trihalomethyl
unsubstituted
substituted
Prior art date
Application number
ZA928727A
Inventor
Alex Cordi
Patrice Desos
Jean Lepagnol
John Randle
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of ZA928727B publication Critical patent/ZA928727B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Compounds of formula (I): <IMAGE> in which: X, Y, Z - which are identical or different, represent a hydrogen atom, a halogen atom or a nitro, cyano, azido, trihalomethyl, linear or branched (C1-C6)alkyl, linear or branched (C1-C6)alkoxy, or amino (unsubstituted or substituted by a linear or branched (C1-C6)acyl group) group, - or else, when they are situated on two adjacent carbons, form, with the carbon atoms to which they are attached, a phenyl ring or a 5- or 6-membered heterocycle containing from 1 to 3 hetero atoms, preferably a 1,2,5-oxadiazole ring, R represents a linear or branched (C1-C6)alkyl, trihalomethyl, phenyl (unsubstituted or substituted by one or a number of halogen atoms or linear or branched (C1-C6)alkyl, trihalomethyl or linear or branched (C1-C6)alkoxy groups), 2-thienyl (unsubstituted or substituted by a halogen atom), naphthyl or styryl group, A represents a CH radical or a nitrogen atom. Medicaments.
ZA928727A 1991-11-14 1992-11-12 3-sulfonylamino-2(1H)-quinolone compounds, process for preparing them and pharmaceutical compositions containing them. ZA928727B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9113977A FR2683818B1 (en) 1991-11-14 1991-11-14 NOVEL 3-SULFONYLAMINO-2- (1H) -QUINOLEINONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Publications (1)

Publication Number Publication Date
ZA928727B true ZA928727B (en) 1993-05-10

Family

ID=9418879

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA928727A ZA928727B (en) 1991-11-14 1992-11-12 3-sulfonylamino-2(1H)-quinolone compounds, process for preparing them and pharmaceutical compositions containing them.

Country Status (11)

Country Link
EP (1) EP0542609B1 (en)
JP (1) JPH06102650B2 (en)
AT (1) ATE111082T1 (en)
AU (1) AU651255B2 (en)
CA (1) CA2082856A1 (en)
DE (1) DE69200394T2 (en)
DK (1) DK0542609T3 (en)
ES (1) ES2064156T3 (en)
FR (1) FR2683818B1 (en)
NZ (1) NZ245127A (en)
ZA (1) ZA928727B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709489B1 (en) * 1993-08-31 1995-10-20 Adir New derivatives of 2- (1H) -quinolineone, their preparation process and the pharmaceutical compositions containing them.
FR2750988B1 (en) * 1996-07-11 1998-09-18 Adir NOVEL 2- (1H) -QUINOLEINONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
EP1690853B1 (en) 1999-01-13 2010-03-10 Bayer HealthCare LLC Use of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CA2378298A1 (en) 1999-08-27 2001-03-08 Lawrence G. Hamann 8-substituted-6-trifluoromethyl-9-pyrido¬3,2-g|quinoline compounds as androgen receptor modulators
PL353792A1 (en) * 1999-08-27 2003-12-01 Ligand Pharmaceuticals Incorporatedligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CA2383565A1 (en) 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
FR2805260A1 (en) * 2000-02-18 2001-08-24 Adir NOVEL 6-SULFAMOYL-3-QUINOLINYL PHOSPHONIC ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2805261A1 (en) * 2000-02-18 2001-08-24 Adir NOVEL 6-AMINO OR 6-HYDRAZINOSULFONYL-3- QUINOLINYL PHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2805262A1 (en) * 2000-02-18 2001-08-24 Adir NOVEL PHYPHONIC ARYL OR HETEROARYL QUINOLINYL ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TWI298068B (en) 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
DE602004007382T2 (en) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven DIARYL UREAS FOR PDGFR MEDIATED DISEASES
CA2536349A1 (en) 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
WO2007053574A2 (en) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3066145A (en) * 1962-02-07 1962-11-27 American Home Prod 3-amino-6-chloro-4-phenyl-2(1h)-quinolone
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
GB9004288D0 (en) * 1990-02-26 1990-04-18 Almirall Lab New 4(1h)quinoline derivatives

Also Published As

Publication number Publication date
NZ245127A (en) 1994-07-26
EP0542609A1 (en) 1993-05-19
DE69200394D1 (en) 1994-10-13
ES2064156T3 (en) 1995-01-16
EP0542609B1 (en) 1994-09-07
AU651255B2 (en) 1994-07-14
DK0542609T3 (en) 1995-03-20
CA2082856A1 (en) 1993-05-15
FR2683818A1 (en) 1993-05-21
ATE111082T1 (en) 1994-09-15
FR2683818B1 (en) 1993-12-31
JPH06102650B2 (en) 1994-12-14
DE69200394T2 (en) 1995-04-27
AU2835192A (en) 1993-05-20
JPH05221997A (en) 1993-08-31

Similar Documents

Publication Publication Date Title
ZA928727B (en) 3-sulfonylamino-2(1H)-quinolone compounds, process for preparing them and pharmaceutical compositions containing them.
TW385309B (en) Novel thiazolidinedione antidiabetic agents
DE10199003I2 (en)
GB8919434D0 (en) Novel compounds
MY101541A (en) Indolizine derivatives, process for preparing them and the compositions containing them
GB8919417D0 (en) Novel compounds
HU9400062D0 (en) Process for the preparation of baccatin iii and 10-deacetyl baccatin iii derivatives
ZA946659B (en) 2(1h)-quinolone compounds process for preparing them and pharmaceutical compositions containing them
DK508484A (en) N-SUBSTITUTED ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
IE790556L (en) Benzylidene derivatives
IL102541A0 (en) Pharmaceutical antihypertensive combination preparations
IL106564A (en) Tetrahydronaphthalene derivatives their preparation and pharmaceutical compositions containing them
GR3018736T3 (en) 20,21-Dinoreburnamine derivatives, substituted in position 15, process for their preparation and novel intermediates so obtained, their use as medicines and compositions containing them
ES488388A1 (en) Thiazole derivatives, their preparation and medicaments containing them.
SE9002445D0 (en) NEW CYCLOBUTAN DERIVATIVE AND PROCEDURE FOR PREPARING THE SAME